Product
PF-06939926
Aliases
Fordadistrogene Movaparvovec
3 clinical trials
3 indications
Indication
Muscular DystrophyIndication
DuchenneIndication
Duchenne muscular dystrophyClinical trial
A PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHYStatus: Active (not recruiting), Estimated PCD: 2024-12-27
Clinical trial
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY AND NON-AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHYStatus: Active (not recruiting), Estimated PCD: 2022-03-28